Wedbush Reaffirms “Outperform” Rating for Kiniksa Pharmaceuticals (NASDAQ:KNSA)
Wedbush restated their outperform rating on shares of Kiniksa Pharmaceuticals (NASDAQ:KNSA – Free Report) in a research note issued to investors on Tuesday morning, RTT News reports. The firm currently has a $30.00 price objective on the stock, up from their prior price objective of $28.00. Wedbush also issued estimates for Kiniksa Pharmaceuticals’ FY2027 earnings […]
More Stories
Metropolitan Bank (NYSE:MCB) versus Ameris Bancorp (NASDAQ:ABCB) Critical Contrast
Metropolitan Bank (NYSE:MCB – Get Free Report) and Ameris Bancorp (NASDAQ:ABCB – Get Free Report) are both finance companies, but...
Wix.com (NASDAQ:WIX) Rating Increased to Buy at StockNews.com
StockNews.com upgraded shares of Wix.com (NASDAQ:WIX – Free Report) from a hold rating to a buy rating in a report...
StockNews.com Initiates Coverage on Global Indemnity Group (NASDAQ:GBLI)
StockNews.com began coverage on shares of Global Indemnity Group (NASDAQ:GBLI – Free Report) in a research note issued to investors...
Keysight Technologies (NYSE:KEYS) Downgraded to Hold Rating by StockNews.com
StockNews.com cut shares of Keysight Technologies (NYSE:KEYS – Free Report) from a buy rating to a hold rating in a...
Bank of South Carolina (NASDAQ:BKSC) Now Covered by Analysts at StockNews.com
StockNews.com initiated coverage on shares of Bank of South Carolina (NASDAQ:BKSC – Free Report) in a research report sent to...
Conifex Timber (TSE:CFF) Trading Down 8% – Here’s What Happened
Conifex Timber Inc. (TSE:CFF – Get Free Report) shares were down 8% during trading on Tuesday . The company traded...